HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Flucytosine (Ancobon)

Subscribe to New Research on Flucytosine

A fluorinated cytosine analog that is used as an antifungal agent.

Also Known As:

Ancobon; Alcobon; Allphar Brand of Flucytosine; Ancotil; CSP Brand of Flucytosine; Dermatech Brand of Flucytosine; ICN Pharmaceuticals Brand of Flucytosine; Roche Brand of Flucytosine; 5-Fluorocytosine; 2(1H)-Pyrimidinone, 4-amino-5-fluoro-

Networked: 798 relevant articles (95 outcomes, 67 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 60
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 319
    - Pyrimidinones: 14
      - Cytosine: 1134
        Flucytosine: 798
        N(4)-hydroxy-5-fluorocytosine

Experts

1.	Harrison, Thomas S: 12 articles (12/2015 - 05/2004)
2.	Kim, Seung U: 8 articles (01/2014 - 01/2009)
3.	Kasahara, Noriyuki: 7 articles (02/2015 - 01/2003)
4.	Hamada, H: 7 articles (08/2012 - 01/2000)
5.	Altaner, Cestmir: 6 articles (09/2014 - 07/2007)
6.	Jarvis, Joseph N: 5 articles (12/2015 - 04/2008)
7.	Loyse, Angela: 5 articles (12/2015 - 07/2008)
8.	Altanerova, Veronika: 5 articles (03/2014 - 07/2007)
9.	Aboody, Karen S: 5 articles (01/2014 - 12/2003)
10.	Matuskova, Miroslava: 5 articles (07/2013 - 07/2007)

Related Diseases

1.	Infection 06/01/1975 - "The fungi infection was successfully eradicated by a single oral dose of 5-Fluorocytosine (20 mg/kg) after each dialysis treatment. " 01/01/1995 - "Flucytosine is effective in the treatment of serious fungal infections. " 08/01/1984 - "The combination of bursectomy and flucytosine treatment cured the infection." 08/01/1978 - "The infection responded well to treatment with 5-fluorocytosine. " 11/01/1975 - "No resistance to 5-fluorocytosine developed, and the candida infection was eradicated. "
2.	Cryptococcosis 11/01/2013 - "Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal." 04/01/2003 - "Flucytosine and cryptococcosis: which in vitro test is the best predictor of outcome?" 08/01/1998 - "Flucytosine (5-FC) monotherapy for cryptococcosis is not advocated because drug resistance emerges during therapy. " 08/01/1998 - "Flucytosine monotherapy for cryptococcosis." 01/19/1980 - "[Treatment of cryptococcosis with flucytosine]."
3.	Cryptococcal Meningitis 10/01/2007 - "The present study demonstrated the substantial increasing of survival time of HIV-infected patients with cryptococcal meningitis by initiated ART even in a resource limited setting (no flucytosine, local combined antiretroviral drugs with NVP based regimens)." 09/01/2014 - "Access to flucytosine for HIV-infected patients with cryptococcal meningitis – an urgent need." 03/01/2012 - "Herein, we present a case of cryptococcal meningitis from China, which was caused by an azole and flucytosine resistant Filobasidium uniguttulatum. " 07/01/2008 - "Sixty-four HIV-seropositive, antiretroviral therapy-naive patients in Cape Town, South Africa, who experienced their first episode of cryptococcal meningitis during the period May 2005-June 2006 were randomized to receive either (1) AmB, 0.7 mg/kg per day, plus flucytosine, 25 mg/kg 4 times per day (group 1; 30 patients); or (2) AmB, 1 mg/kg per day, plus flucytosine, 25 mg/kg 4 times per day (group 2; 34 patients). " 03/01/2007 - "Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis."
4.	Candidiasis (Moniliasis) 10/01/2009 - "Clearance of intravenous 5-fluorocytosine during continuous venovenous haemodiafiltration in a patient with hepatosplenic candidiasis." 09/01/1988 - "[Clinical efficacy of flucytosine on urinary candidiasis]." 01/01/1985 - "In a previous study with flucytosine (5-FC) susceptibility of 40 Candida albicans isolates in vitro proved statistically correlated with response in systemic murine candidiasis in vivo, although exceptions occurred with individual isolates. " 11/01/2006 - "We used a pharmacodynamic model of disseminated candidiasis to define an in vivo drug exposure breakpoint for flucytosine (5FC) against Candida albicans. " 11/01/2005 - "For acute disseminated candidiasis, the combination of DAMB plus flucytosine is recommended. "
5.	Acquired Immunodeficiency Syndrome (AIDS) 10/01/1999 - "Disseminated acanthamoeba infection in a patient with AIDS: response to 5-fluorocytosine therapy." 12/09/1988 - "Anaphylaxis to flucytosine in a patient with AIDS." 06/01/1998 - "These data indicate that treatment with fluconazole and short-term flucytosine is a cost-effective and safe regimen that improves the quality of life for patients with AIDS-associated CM in developing countries where human immunodeficiency virus is endemic." 04/01/1988 - "Mycological-diagnostic assessment of the efficacy of amphotericin B + flucytosine to control Cryptococcus neoformans in AIDS patients." 02/01/1995 - "Thirty-one consecutive AIDS patients with cryptococcal disease were enrolled in a study of the efficacy and safety of short-course primary treatment with a relatively high dose of amphotericin B (1 mg/[kg.d] for 14 days); 26 patients also received flucytosine (100-150 mg/[kg.d], given either intravenously or orally). "

Related Drugs and Biologics

1.	Amphotericin B (Amphotericin)
2.	Fluconazole (Zonal)
3.	Itraconazole (Sporanox)
4.	Cytosine Deaminase
5.	liposomal amphotericin B
6.	Ketoconazole (Nizoral)
7.	Antifungal Agents
8.	Systemic candidiasis
9.	Fluorouracil (Carac)
10.	Ganciclovir (Cytovene)

Related Therapies and Procedures

1.	Transplantation (Transplant Recipients)
2.	Drug Therapy (Chemotherapy)
3.	Aftercare (After-Treatment)
4.	Decompression
5.	Atherectomy